NCT05075512View on ClinicalTrials.gov

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2026

Conditions
Breast Neoplasm Female
Interventions
DRUG

anlotinib, fulvestrant

anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle

Trial Locations (1)

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER